Navigation Links
Jennerex Appoints Samantha Miller as Vice President of Corporate Development

SAN FRANCISCO, Jan. 13 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biotherapeutics company, is pleased to announce that Samantha Miller has been appointed to the position of Vice President of Corporate Development.

Ms. Miller has over 15 years of biotechnology and pharmaceutical business development experience, and has negotiated, executed and managed numerous global partnerships, as well as regional partnerships in the United States, Europe, Japan and elsewhere. She has been involved in executing over 30 partnerships and licenses, with companies such as GlaxoSmithKline, Eli Lilly, Johnson & Johnson, AstraZeneca, Astellas and others.

Ms. Miller has held senior positions in business development, including the title of Vice President, in various companies including Anesiva, Theravance, Scios Pharmaceuticals, Onyx Pharmaceuticals and Procter & Gamble Pharmaceuticals.

"Samantha is an outstanding addition to our executive management team. As Jennerex continues to report compelling Phase 1 and 2 clinical data from its oncology programs, Samantha joins us at an opportune time for the development of additional strategic partnerships," said David H. Kirn, M.D., President and Chief Executive Officer. "We have clear regulatory pathways to large global cancer markets with multiple products, and Samantha's addition to the Jennerex team further endorses the potential of the Company's product platform," added Dr. Kirn.

Ms. Miller holds a BS in Biochemistry/ Cell Biology from UCSD, and she holds Masters degrees in both Immunology and in Business Administration (MBA) from the University of Rochester.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
4. Codexis Appoints Singapore Laboratories Managing Director
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. NeurogesX Appoints New Director to the Board
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 24, 2015 , ... The Academy of Model Aeronautics (AMA), led by its ... as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV ... embraced this type of racing and several new model aviation pilots have joined the ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):